PPT-Chapter 10 Drug Therapy in Pediatric Patients

Pediatric Patients All patients younger than16 years Respond differently to drugs than the rest of the population More sensitive to drugs than other patients are Show greater individual variation. Athos Bousvaros MD, MPH. Advances in IBD Dec 2014. Disclosures (last 12 months). Consultant. Takeda/Millennium. Dyax. Cubist. Peabody Arnold (litigation). Research support. Prometheus. Questions. Should we use combination therapy in our pediatric IBD patients?. Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder. CNS Stimulants. Increase the activity of CNS neurons. Enhance neuronal excitation; a few suppress neuronal inhibition. In sufficient doses, all can cause convulsions. Impact on Pharmacy Practice. Kimberly Zammit, . PharmD. , BCPS, FASHP. NYS Board of Pharmacy . Chair, CDTM Implementation Committee. September 23, 2014 . Disclosures. None to report. Collaborative Drug Therapy Management. Geriatric Patients. Disproportionately high prescription drug use exists in the elderly.. 12% of Americans are age 65 years or older.. This 12% consumes 31% of prescribed drugs.. Geriatric patients experience more adverse drug reactions and drug-drug interactions than younger patients do.. Kenneth L. Kirsh. , . Ph.D.. Clinical Research Educator and Research Scientist. Millennium . Laboratories. Millennium Research Institute. San Diego, CA. The Opioid Pendulum. Opiophobia. Balance of Addiction Medicine and Pain Management Principles. Enrolling Adolescents into Adult Phase 3 Trials Case Study: Inflammatory Bowel Disease Tara Altepeter, MD Clinical Team Leader Division of Gastroenterology and Inborn Errors Products Office of New Drugs ataxia telangiectasia . and advanced stage high grade mature B. -cell malignancies.. Pediatr. . Blood Cancer. . 2014 February ; 61(2): 360–362. . There is no consensus regarding the optimal strategy for treating children with AT who develop a hematopoietic malignancy.. Additional copies are available from Office of Communications Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave Hillandale Bldg nhl. Presenting by . F.Malek. M.D. Assistant Professor Ped Hematologist & Oncologist . Mofid. Children’s Hospital. Introduction. The non-Hodgkin lymphomas (NHLs) occurring in children and adolescents and young adults (AYA) are characterized by various age-related differences in tumor biology and survival. . Dr Arif Hashmi. Objectives. a. . Discuss the principles of prescribing in . pediatric . and geriatric age groups. . b. Discuss the pharmacokinetic and pharmacodynamics differences in . pediatric, . geriatric and adult age groups. . Diana Deister, MS, MD. Child and Adolescent Psychiatrist. Adolescent Substance Use and Addictions Program. Division of Developmental Medicine. Boston Children’s Hospital. October 24. th. , . 2017. Disclosure. Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale B United States Renal Data System. 2012 Annual Data Report. Adjusted all-cause rehospitalization . rates in pediatric patients 30 days . after live hospital discharge. Figure 8.1 (Volume 2). ESRD patients age 0–19. . Dr Arif Hashmi. Objectives. a. . Discuss the principles of prescribing in . pediatric . and geriatric age groups. . b. Discuss the pharmacokinetic and pharmacodynamics differences in . pediatric, . geriatric and adult age groups. .